Novel cerebrospinal fluid biomarkers correlating with shunt responsiveness in patients with idiopathic normal pressure hydrocephalus.

Humans Hydrocephalus, Normal Pressure / cerebrospinal fluid Prospective Studies Proteomics Alzheimer Disease / cerebrospinal fluid Biomarkers / cerebrospinal fluid 14-3-3 Proteins
Cerebrospinal fluid Fluid biomarkers Idiopathic normal pressure hydrocephalus Proteomics Shunt response Tandem mass tag

Journal

Fluids and barriers of the CNS
ISSN: 2045-8118
Titre abrégé: Fluids Barriers CNS
Pays: England
ID NLM: 101553157

Informations de publication

Date de publication:
05 Jun 2023
Historique:
received: 07 03 2023
accepted: 09 05 2023
medline: 7 6 2023
pubmed: 6 6 2023
entrez: 5 6 2023
Statut: epublish

Résumé

Idiopathic Normal pressure hydrocephalus (iNPH) is a form of adult hydrocephalus that is clinically characterized by progressive gait impairment, cognitive dysfunction, and urinary incontinence. The current standard method of treatment involves surgical installation of a CSF diversion shunt. However, only a fraction of patients shows an alleviation of symptoms from shunt surgery. Thus, the purpose of this prospective explorative proteomic study was to identify prognostic CSF biomarkers to predict shunt responsiveness in iNPH patients. Further, we evaluated the ability of the core Alzheimer's disease (AD) CSF biomarkers phosphorylated (p)-tau, total (t)-tau, and amyloid-β 1-42 (Aβ We conducted a tandem mass tag (TMT) proteomic analysis of lumbar CSF from 68 iNPH patients, sampled pre-shunt surgery. Tryptic digests of CSF samples were labelled with TMTpro reagents. The TMT multiplex samples were fractionated in 24 concatenated fractions by reversed-phase chromatography at basic pH and analysed by liquid chromatography coupled to mass spectrometry (LC-MS) on an Orbitrap Lumos mass spectrometer. The relative abundances of the identified proteins were correlated with (i) iNPH grading scale (iNPHGS) and (ii) gait speed change 1 year after surgery from baseline to identify predictors of shunt responsiveness. We identified four CSF biomarker candidates which correlated most strongly with clinical improvement on the iNPHGS and were significantly changed in shunt-responsive compared to shunt-unresponsive iNPH patients 1 year post-surgery: FABP3 (R = - 0.46, log FABP3, MIF, ANXA4, B3GAT2, ITGB1, YWHAG, OLFM2, TGFBI and DSG2 in CSF are promising prognostic biomarker candidates to predict shunt responsiveness in iNPH patients.

Sections du résumé

BACKGROUND BACKGROUND
Idiopathic Normal pressure hydrocephalus (iNPH) is a form of adult hydrocephalus that is clinically characterized by progressive gait impairment, cognitive dysfunction, and urinary incontinence. The current standard method of treatment involves surgical installation of a CSF diversion shunt. However, only a fraction of patients shows an alleviation of symptoms from shunt surgery. Thus, the purpose of this prospective explorative proteomic study was to identify prognostic CSF biomarkers to predict shunt responsiveness in iNPH patients. Further, we evaluated the ability of the core Alzheimer's disease (AD) CSF biomarkers phosphorylated (p)-tau, total (t)-tau, and amyloid-β 1-42 (Aβ
METHODS METHODS
We conducted a tandem mass tag (TMT) proteomic analysis of lumbar CSF from 68 iNPH patients, sampled pre-shunt surgery. Tryptic digests of CSF samples were labelled with TMTpro reagents. The TMT multiplex samples were fractionated in 24 concatenated fractions by reversed-phase chromatography at basic pH and analysed by liquid chromatography coupled to mass spectrometry (LC-MS) on an Orbitrap Lumos mass spectrometer. The relative abundances of the identified proteins were correlated with (i) iNPH grading scale (iNPHGS) and (ii) gait speed change 1 year after surgery from baseline to identify predictors of shunt responsiveness.
RESULTS RESULTS
We identified four CSF biomarker candidates which correlated most strongly with clinical improvement on the iNPHGS and were significantly changed in shunt-responsive compared to shunt-unresponsive iNPH patients 1 year post-surgery: FABP3 (R = - 0.46, log
CONCLUSION CONCLUSIONS
FABP3, MIF, ANXA4, B3GAT2, ITGB1, YWHAG, OLFM2, TGFBI and DSG2 in CSF are promising prognostic biomarker candidates to predict shunt responsiveness in iNPH patients.

Identifiants

DOI: 10.1186/s12987-023-00440-5 PMID: 37277809 PMC: PMC10243080
pubmed: 37277809
doi: 10.1186/s12987-023-00440-5
pii: 10.1186/s12987-023-00440-5
pmc: PMC10243080
doi:

Substances chimiques

Biomarkers 0
YWHAG protein, human 0
14-3-3 Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

40

Subventions

Organisme : NIH HHS
ID : #1R01AG068398-01
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Dement Geriatr Cogn Disord. 2008;25(1):37-45
pubmed: 18025828
Gene. 2002 Aug 21;296(1-2):29-36
pubmed: 12383500
Ann Neurol. 2017 Oct;82(4):503-513
pubmed: 28892572
Neurology. 2005 Jul 12;65(1):102-6
pubmed: 16009893
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
J Neurosurg. 2019 May 24;132(6):1773-1784
pubmed: 31125971
Cell Signal. 2021 Aug;84:110028
pubmed: 33940163
Eur J Neurol. 2021 Apr;28(4):1153-1159
pubmed: 33316127
eNeurologicalSci. 2017 Apr 11;7:27-31
pubmed: 29302622
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Acta Neurol Scand. 2007 Nov;116(5):333-9
pubmed: 17922727
J Gen Physiol. 2003 May;121(5):413-25
pubmed: 12695484
Neurology. 1989 Sep;39(9):1159-65
pubmed: 2771064
J Neurol Sci. 2018 Apr 15;387:21-26
pubmed: 29571865
Neurosurg Focus. 2020 Oct;49(4):E8
pubmed: 33002861
Lancet Neurol. 2015 Jun;14(6):585-94
pubmed: 25934242
Can J Neurol Sci. 2018 Jan;45(1):3-10
pubmed: 29125088
Clin Interv Aging. 2016 May 17;11:665-81
pubmed: 27274215
Parkinsonism Relat Disord. 2021 Jan;82:56-60
pubmed: 33248394
Int Rev Neurobiol. 2020;154:413-436
pubmed: 32739013
Br J Anaesth. 2013 Sep;111(3):424-32
pubmed: 23650253
Mol Neurobiol. 2009 Oct;40(2):122-38
pubmed: 19554483
Int J Biochem Mol Biol. 2012;3(2):152-64
pubmed: 22773956
Cell Mol Life Sci. 2019 May;76(10):1833-1863
pubmed: 30770953
Fluids Barriers CNS. 2022 Jun 11;19(1):50
pubmed: 35690759
J Clin Med. 2021 Mar 06;10(5):
pubmed: 33800840
Fluids Barriers CNS. 2016 Nov 22;13(1):20
pubmed: 27876063
Fluids Barriers CNS. 2019 Jul 25;16(1):21
pubmed: 31340831
J Neurosurg. 2018 Jan 19;130(1):121-129
pubmed: 29350601
Neuropathol Appl Neurobiol. 2018 Aug;44(5):474-490
pubmed: 28627088
Fluids Barriers CNS. 2012 Mar 23;9(1):7
pubmed: 22444461
Alzheimers Dement. 2011 Sep;7(5):509-13
pubmed: 21723206
Acta Neurochir (Wien). 2022 Jul;164(7):1719-1746
pubmed: 35230552
Acta Neurochir (Wien). 2017 Dec;159(12):2293-2300
pubmed: 28889317
Acta Neurochir (Wien). 2013 Oct;155(10):1977-80
pubmed: 23975646
Cerebrospinal Fluid Res. 2008 Apr 25;5:9
pubmed: 18439296
Neurosurgery. 2005 Sep;57(3 Suppl):S4-16; discussion ii-v
pubmed: 16160425
Front Neurol. 2020 Jun 02;11:376
pubmed: 32581990
J Clin Med. 2021 Jul 06;10(14):
pubmed: 34300173
Fluids Barriers CNS. 2012 Nov 09;9(1):23
pubmed: 23140302
J Alzheimers Dis. 2021;81(3):1117-1130
pubmed: 33896842
PLoS One. 2014 Mar 17;9(3):e91974
pubmed: 24638077
Front Cell Dev Biol. 2014 Feb 26;2:6
pubmed: 25364714
Neurol Med Chir (Tokyo). 2021 Feb 15;61(2):63-97
pubmed: 33455998
J Neurosurg. 2022 Mar 11;:1-13
pubmed: 35276651
Front Aging Neurosci. 2021 Jul 08;13:689098
pubmed: 34305569
Neurol Res. 2021 Jan;43(1):78-85
pubmed: 33059546
J Neurosurg. 2019 Oct 4;:1-6
pubmed: 31585427
J Eval Clin Pract. 2014 Aug;20(4):295-300
pubmed: 24798823
J Cell Sci. 2009 Dec 15;122(Pt 24):4401-7
pubmed: 19955337
Neurology. 2012 May 15;78(20):1568-75
pubmed: 22517093

Auteurs

Sophia Weiner (S)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. sophia.weiner@gu.se.

Antti Junkkari (A)

Department of Neurosurgery, NeuroCenter, Kuopio University Hospital and Neurosurgery, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.

Mathias Sauer (M)

Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Antti Luikku (A)

Department of Neurosurgery, NeuroCenter, Kuopio University Hospital and Neurosurgery, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.

Tuomas Rauramaa (T)

Department of Pathology, Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland.

Tarja Kokkola (T)

Department of Neurology, Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland.

Sanna-Kaisa Herukka (SK)

UK Dementia Research Institute, London, UK.

Kaj Blennow (K)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Henrik Zetterberg (H)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
UK Dementia Research Institute, London, UK.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.
Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.

Ville Leinonen (V)

Department of Neurosurgery, NeuroCenter, Kuopio University Hospital and Neurosurgery, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.

Johan Gobom (J)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Novel cerebrospinal fluid biomarkers...
questionsmedicales.fr › Maladies du système nerveux › Maladies du système nerveux central › Encéphalopathies › Hydrocéphalie › Hydrocéphalie chronique de l'adulte › Novel cerebrospinal fluid biomarkers...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Novel cerebrospinal fluid biomarkers...
questionsmedicales.fr › Disciplines des sciences naturelles › Chimie › Biochimie › Protéomique › Novel cerebrospinal fluid biomarkers...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › Novel cerebrospinal fluid biomarkers...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Novel cerebrospinal fluid biomarkers...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protéines adaptatrices de la transduction du signal › Protéines 14-3-3 › Novel cerebrospinal fluid biomarkers...